Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Wednesday July io

WePeB5976 Importance and characteristics of immigrants
from Sub-Saharan Africa in the Swiss HIV Cohort
Study
H Furrer, C Staehelin M Egger, B Ledergerber,
M Battegay, M Rickenbach (Switzerland)
WePeB5977 Predictors of persistent use of newer
antiretroviral agents over time in a low-income
U.S. population with HIV/AIDS
S Crystal, U Sambamoorthi, P Moynihan,
E McSpiritt (United States)
WePeB5978 Use of Cobas Amplicator HCV test for the
detection of HCV RNA in HIV-1 infected patients
H H Lin, HM Chiou, S J Lee, C K Huang,
Y S Chen, Y C Liu (Taiwan)
WePeB5979 Antiretroviral resistance in Swedish HIV-2
patients
E Brandin L Lindborg, C Brostrdm, K Gyllensten,
]Albert (Sweden)
WePeB598o Production of nitric oxide in HIV-1 infected
patients treated with IL-2
D Torre, F Speranza, S Ghezzi, G Tambussi,
A Lazzarin, R Tambini, G Poli (Italy)
WePeB5981 Failure of interleukin-2 to restore proliferation in
cd4+ t cells occurs in a subpopulation of HIVinfected patients and is not related to levels of
interleukin-2 receptor expression
S F Sieg, M M Lederman (United States)
WePeB5982 Demographics and visit compliance in SILCAAT, a
large international phase Ill clinical endpoint trial
with IL-2 as an immune-based therapy adjunctive
to ART
J P Routy for the International S/LCAAT Team
(Venezuela)
WePeB5983 The use of subcutaneous recombinant
interleukin-2 with highly active antiretroviral
therapy in H IV infection
J E Ribeiro, AS Souza MB C Lima, MA Silva,
M L E Pires, A C Varela, H C Maleh,
CM S Machado, EA Magalhdes (Brazil)
WePeB5984 Decreased levels of plasma Retinot binding
protein and Transthyretin in patients undergoing
interleukin-2 therapy
V Natara an, T Garnett, Y Badralmaa, J A Metcalf,
]A Kovacs, H C Lane (United States)
WePeB5985 Baseline characteristics of patients enrolled in
ESPRIT
J C Lopez E Bouza, P Domingo, B Clotet,
H Knobel, L FL Cortes, J M Gatell, J Sanz,
E Fernandez-Cruz (Spain)
WePeB5986 Retroviral vectors for inhibition of HIV entry and
replication
M Eqelhoer H Martinius, G Brandenburg,
P Schult-Dietrich, F Vorpahl, D von Laer (Germany)
WePeB5987 Effect of multivitamin supplementation on genital
tract shedding of human immunodeficiency virus
type 1: results of a randomized trial
R S McClelland, I M Baeten', I Overbaugh,
B A Richardson', K Mandaliya2, S Emery',
L Lavreys, 1 0 Ndinya-Achola2, JI Bwayo2,
I K Kreiss (lUnited States; 2Kenya)
WePeB5988 Zinc deficiency affects disease progression in
HIV+ drug users
M K Baum, A Campa, S Lai, H Lai, S Sales, Z Yang,
I Scott, B Page (United States)
WePeB5989 Vitamin A supplementation and HIV-l shedding in
women: results of a randomized clinical trial
]M Baeten, R S McClelland, I Overbaugh,

B A Richardson', S Emery1, L Lavreys',
K Mandaliya2, D D Bankson', 1 0 Ndinya-Achola2,
Jj Bwayo2, JK Kreiss1 (lUnited States; 2Kenya)

WePeB599o The effect of nutrition and exercise advice on
lipid profiles of HIV+ patients with hyperlipidemia
M Liss, C Vaamonde, B Boyle (United States)
WePeB5991 Potential benefit of selenium as an adjuvant
therapy in the HAART era
G Shor-Posner, M J Miguez, X Burbano,
A Rodriguez, P Ruiz, G Zhang, M K Baum
(United States)
WePeB5992 Longitudinal assessment of growth among children
born to HIV-infected mothers, in Sao Paulo, Brazil
W Queiroz, M Della Negra, I AC Taddei,
F Colugnati, CL Yu, A P G Pochini, C SoraggiNeto, D P Pacola (Brazil)
WePeB5993 Highly active antiretroviral therapy based on a
protease inhibitor -sparing regimen, reconstitutes
muscle mass in HIV-infected individuals with
wasting syndrome but not in those with
moderate or no weight loss
K Zuniqa-Roiz, A C Hernandez-Daly, K] Torres,
]A Zuniga, M E Mayar-Maya, G Reyes-Teran
(Mexico)
WePeB5994 Longitudinal growth assessment in HIV exposed
infants in Belo Horizonte, Brazil
C A Araio, M S A Barbosa, CM N Oliveira,
R M Pereira, MA Vasconcelos, L I Melo, I A Pinto
(Brazil)
WePeB5995 Increased risk of developing cervical dysplasia in
HIV infected women in the HAART era
X Burbano, M Miguez-Burbano, R Hernandez,
A Rodriguez, P Ruiz, R Lecusay, G Shor-Posner
(United States)
WePeB5996 Strategies for Immune Reconstitution: Selenium
Cytokine Action in HIV/AIDS
MI Miguez-Burbano, P Ruiz, A Rodriguez,
X Burbano, G Castillo, L M Pineda, R Lecusay,
G Shor-Posner (United States)
WePeB5997 Anthropometric equations select HIV+ men and
women with distinctly abnormal fat accumulation
and distribution
D P Kotler, N Muurahainen, P Chang,
ES Engelson, J Wang, S B Heymsfeld, J M Gertner
(United States)
WePeB5998 Vitamin E levels increase with antiretroviral
treatment without additional supplementation
FJ Vilar A C Stalford, W Taylor, A Shenkin,
B K Park, M Pirmohamed (United Kingdom)
WePeB5999 The availability of the UNAIDs recommended
conditions for the safe practice of formula
feeding and actual mothers' infant feeding
practices in Botswana
B Mduma', M Phegelo', K Mompati, 0 Ntshebe,
J Sibiya, L Gabaitsewe, T Baile', P Mazhani',
C Luo, N C Rollins2, F] JWillumsen2, S Kleintjes'
('Botswana; 2South Africa)
WePeB6oo Acupuncture cross-over trial: can acupuncture
effectively control side-effects of HIVcombination therapy?
EA S Sommers, K E P Porter (United States)
WePeB6ooi Does complementary and alternative medicine
(cam) improve quality of life in people with
HIV/AIDS
N Robinson L Pedro, D Sumeray (United
Kingdom)
WePeB6002 Immunological memory and activation status of
HIV positive patients: non-treated versus
ModucareTM treated patient groups
P jD Boui, I H Lamprecht, G Classens, A Clark,

W Brittle, M Freestone (South Africa)

Wednesday

164 Final Program